Tocainide

Tocainide is an antiarrhythmic agent which is primarily used in the treatment of ventricular arrhythmias. It was developed in the 1970s by Pfizer and is similar in structure to the local anesthetic lidocaine. However, it is not currently widely used due to its potential for serious side effects.

Pharmacology

Tocainide works by blocking the fast sodium channels in the heart, which are responsible for the rapid depolarization phase of the cardiac action potential. This results in a decrease in the rate of electrical conduction through the heart, which can help to restore a normal rhythm in patients with certain types of arrhythmias.

Clinical use

Tocainide is used primarily in the treatment of ventricular arrhythmias, such as ventricular tachycardia and ventricular fibrillation. It is also sometimes used in the treatment of atrial fibrillation and atrial flutter, although it is not the first-line treatment for these conditions.

Side effects

The most common side effects of tocainide include nausea, vomiting, dizziness, and fatigue. More serious side effects can include cardiac arrest, heart failure, and pulmonary fibrosis. Due to these potential side effects, tocainide is typically only used when other treatments have failed.

History

Tocainide was developed in the 1970s by Pfizer as a potential treatment for arrhythmias. It is structurally similar to lidocaine, a local anesthetic that is also used as an antiarrhythmic agent. However, due to its potential for serious side effects, tocainide is not currently widely used.

See also

• Antiarrhythmic agent
• Ventricular arrhythmia
• Pfizer

• 
  Chemical structure of Tocainide
• Synthesis pathway of Tocainide
  Synthesis pathway of Tocainide